Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) has seen a rise in its stock price by 0.63 in relation to its previous close of 11.04. However, the company has experienced a 3.54% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-06 that RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.
Is It Worth Investing in Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Right Now?
The stock has a 36-month beta value of 1.10. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BCRX is 200.47M, and at present, short sellers hold a 10.46% of that float. On June 10, 2025, the average trading volume of BCRX was 4.53M shares.
BCRX’s Market Performance
BCRX’s stock has seen a 3.54% increase for the week, with a 12.00% rise in the past month and a 50.54% gain in the past quarter. The volatility ratio for the week is 0.95%, and the volatility levels for the past 30 days are at 2.21% for Biocryst Pharmaceuticals Inc The simple moving average for the past 20 days is 5.05% for BCRX’s stock, with a 36.27% simple moving average for the past 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Cantor Fitzgerald repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to Cantor Fitzgerald is $20 based on the research report published on April 29, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $15. The rating they have provided for BCRX stocks is “Outperform” according to the report published on February 25th, 2025.
JP Morgan gave a rating of “Overweight” to BCRX, setting the target price at $10 in the report published on November 20th of the previous year.
BCRX Trading at 22.77% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.77% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Hutson Nancy J, who sale 7,000 shares at the price of $7.54 back on Dec 13 ’24. After this action, Hutson Nancy J now owns 86,638 shares of Biocryst Pharmaceuticals Inc, valued at $52,780 using the latest closing price.
Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc, proposed sale 7,000 shares at $7.51 during a trade that took place back on Dec 13 ’24, which means that Hutson Nancy J is holding shares at $52,584 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.97 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc stands at -0.11. The total capital return value is set at 0.1.
Based on Biocryst Pharmaceuticals Inc (BCRX), the company’s capital structure generated 2.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at -1.76. The interest coverage ratio of the stock is 0.34.
Currently, EBITDA for the company is 12.81 million with net debt to EBITDA at 17.05. When we switch over and look at the enterprise to sales, we see a ratio of 5.99. The receivables turnover for the company is 5.39for trailing twelve months and the total asset turnover is 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.93.
Conclusion
To sum up, Biocryst Pharmaceuticals Inc (BCRX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
